Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

Ivana Sullivan, David Planchard, Ivana Sullivan, David Planchard

Abstract

Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second-generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell-signaling pathways that drive the growth of tumor cells. Unfortunately, the majority of patients develop resistance to them after a median duration of response of around 10 months, and in over half of these patients the emergence of the EGFR T790M resistance mutation is detected. Osimertinib is an oral, highly selective, irreversible inhibitor of both EGFR-activating mutations and the T790M-resistance mutation, while sparing the activity of wild-type EGFR This article reviews clinical trial development of osimertinib in patients with NSCLC, presenting efficacy and safety evidence for its value in the EGFR T790M mutation-positive population and in different settings, including patients with metastatic disease. The preclinical background of clinically acquired resistance to osimertinib is presented and the combination tactics being investigated in an attempt to circumvent this are addressed.

Keywords: AZD9291; T790M; ctDNA; epidermal growth factor receptor; metastatic; non-small cell lung cancer; osimertinib.

Conflict of interest statement

Conflict of interest statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

© The Author(s), 2016.

Figures

Figure 1.
Figure 1.
Osimertinib development from phase I–III trials in advancedEGFR-mutant NSCLC. *No limit on prior EGFR-TKI or systemic regimens. $Cisplatin or carboplatin. aNSCLC, advanced non-small cell lung cancer; EGFRm, epidermal growth factor receptor mutant; NCT number, ClinicalTrials.gov identifier; PD, progressive disease; qd, once daily; TKI, tyrosine kinase inhibitor.
Figure 2.
Figure 2.
Phase I BLOOM trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD3759 in EGFR-mutant NSCLC and osimertinib 160 mg daily in EGFR-mutant NSCLC with central nervous system disease. bid, twice daily; BM, brain metastasis;EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; qd, once daily; TKI, tyrosine kinase inhibitor.
Figure 3.
Figure 3.
Mechanisms of resistance to third-generation EGFR TKIs osimertinib and rociletinib. Data from Piotrowska et al.[2015], Thress et al. [2015], Yu et al. [2015], Planchard et al. [2015], and Kim et al. [2015]. amp, amplification; EGFR, epidermal growth factor receptor; SCLC, small cell lung cancer; TKI, tyrosine kinase inhibitor.
Figure 4.
Figure 4.
Potential treatment algorithm for patients with EGFR-mutated advanced NSCLC. CT, chemotherapy; EGFR, epidermal growth factor receptor; MoR, mechanism of resistance; mPFS, median progression-free survival; ORR, overall response rate; qd, once daily; SCLC, small cell lung cancer; TKI, tyrosine kinase inhibitor.

References

    1. Ahn M., Tsai C., Yang J., Shepherd F., Satouchi M., Kim D., et al. (2015) AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from phase II studies. Eur J Cancer 51: S625–S626.
    1. Ahn M., Yang J., Yu H., Saka H., Ramalingam H., Huang X. (2016) Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. Sixth IASLC/ESMO. Eur Lung Cancer Conf 11: S115; abstract LBA2.
    1. Barlesi F., Mazieres J., Merlio J., Debieuvre D., Mosser J., Lena H., et al. (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet Oncol 387: 1415–1426.
    1. Chamberlain M., Kormanik P. (1998) Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 5: 506–512.
    1. Cross D., Ashton S., Ghiorghiu S., Eberlein C., Nebhan C., Spitzleet P., et al. (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4: 1046–1061.
    1. Eberlein C., Stetson D., Markovets A., Al-Kadhimi K., Lai Z., Fisher P., et al. (2015) Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res 75: 2489–2500.
    1. Ellis P., Shepherd F., Millward M., Perrone F., Seymour L., Liu G., et al. (2014) Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol 15: 1379–1388.
    1. Ercan D., Choi H., Yun C., Capelletti M., Xie T., Eck M., et al. (2015) EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res 21: 3913–3923.
    1. Gainor J., Shaw A. (2013) Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 31: 3987–3996.
    1. Goss G., O’Callaghan C., Lorimer I., Tsao M., Masters G., Jett J., et al. (2013) Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 31: 3320–3326.
    1. Goto Y., Nokihara H., Murakami H., Shimizu T., Seto T., Krivoshik A., et al. (2015) ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: preliminary results of first-in-human phase I study in Japan. J Clin Oncol 33(Suppl.); abstract 8014.
    1. Hata A., Niederst M., Archibald H., Gomez-Caraballo M., Siddiqui F., Mulvey H., et al. (2016) Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 22: 262–269.
    1. Hoffknecht P., Tufman A., Wehler T., Pelzer T., Wiewrodt R., Schütz M., et al. (2015) Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 10: 156–163.
    1. Husain H., Kosco K., Vibat C., Melnikova V., Erlander M., Cohen E., et al. (2015) Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma. J Clin Oncol 33(Suppl.); abstract 8081.
    1. Inukai M., Toyooka S., Ito S., Asano H., Ichihara S., Soh J., et al. (2006) Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66: 7854–7858.
    1. Jamal-Hanjani M., Spicer J. (2012) Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 18: 938–944.
    1. Janjigian Y., Park B., Zakowski M., Ladanyi M., Pao W., D’Angelo S., et al. (2011) Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol 6: 569–575.
    1. Janjigian Y., Smit E., Groen H., Horn L., Gettinger S., Camidge D., et al. (2014) Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 4: 1036–1045.
    1. Jänne P., Yang J., Kim D., Planchard D., Ohe Y., Ramalingam S., et al. (2015) A AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372: 1689–1699.
    1. Jia Y., Juarez J., Li J., Manuia M., Niederst M., Tompkins C., et al. (2016). EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Res 76: 1591–1602.
    1. Kelly K., Altorki N., Eberhardt W., O’Brien M., Spigel D., Crinò L., et al. (2015) Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol 33: 4007–4014.
    1. Kim D., Yang J., Cross D., Ballard P., Yang P., Yates J., et al. (2014) Preclinical evidence and clinical cases of AZD9291 activity in EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases (BM). Ann Oncol 25(Suppl. 4): iv146–iv164.
    1. Kim T., Song A., Kim D., Kim S., Ahn Y., Keam B., et al. (2015) Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol 10: 1736–1744.
    1. Kris M., Johnson B., Berry L., Kwiatkowski D., Iafrate A., Wistuba I., et al. (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311: 1998–2006.
    1. Kuiper J., Hendriks L., van der Wekken A., de Langen A., Bahce I., Thunnissen E., et al. (2015) Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer 89: 255–261.
    1. Lee J., Park K., Han J., Lee K., Kim J., Cho E., et al. (2015) Clinical activity and safety of the EGFR mutant-specific inhibitor, BI1482694, in patients (pts) with T790M-positive NSCLC. Ann Oncol 26(Suppl. 9): ix128–ix129.
    1. Lee Y., Choi H., Kim S., Chang J., Moon J., Park Y., et al. (2010) Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 116: 1336–1343.
    1. Liao B., Lee J., Lin C., Chen Y., Chang C., Ho C., et al. (2015) Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol 10: 1754–1761.
    1. Li H., Hu H., Wang R., Pan Y., Wang L., Li Y., et al. (2014) Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther 7: 513–524.
    1. Li S., Schmitz K., Jeffrey P., Wiltzius J., Kussie P., Ferguson K. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301–311.
    1. Lynch T., Bell D., Sordella R., Gurubhagavatula S., Okimoto R., Brannigan B., et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.
    1. Miller V., Hirsh V., Cadranel J., Chen Y., Park K., Kim S., et al. (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13: 528–538.
    1. Mok T., Wu Y., Thongprasert S., Yang C., Chu D., Saijo N., et al. (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957.
    1. Naumov G., Nilsson M., Cascone T., Briggs A., Straume O., Akslen L., et al. (2009) Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15: 3484–3494.
    1. Niederst M., Hu H., Mulvey H., Lockerman E., Garcia A., Piotrowska Z., et al. (2015) The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 21: 3924–3933.
    1. Omuro A., Kris M., Miller V., Franceschi E., Shah N., Milton D., et al. (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103: 2344–2348.
    1. Oxnard G., Thress K., Paweletz C., Stetson D., Dougherty B., Markovets A., et al. (2015) Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer. J Thorac Oncol 10(9 Suppl. 2); ORAL 17.07.
    1. Paez J., Jänne P., Lee J., Tracy S., Greulich H., Gabriel S., et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500.
    1. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. (2004) EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–13311.
    1. Park K., Lee J., Lee K., Kim J., Cho B., Min Y., et al. (2016) BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: efficacy and safety at the RP2D. J Clin Oncol 34 (Suppl.); abstract 9055
    1. Pennell N., Neal J., Chaft J., Azzoli C., Jänne P., Govindan R., et al. (2014) SELECT: a multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. J Clin Oncol 32(Suppl.); abstract 7514.
    1. Piotrowska Z., Niederst M., Karlovich C., Wakelee H., Neal J., Mino-Kenudson M., et al. (2015) Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 5: 713–722.
    1. Planchard D., Brown K., Kim D., Kim S., Ohe Y., Felip E., et al. (2016) Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol 77: 767–776.
    1. Planchard D., Loriot Y., André F., Gobert A., Auger N., Lacroix L., Soria J. (2015) EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 26: 2073–2078.
    1. Ramalingam S., Yang J., Lee C., Kurata T., Kim D. (2016) Osimertinib (AZD9291) as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two phase I expansion cohorts. J Thorac Oncol 11(Suppl. 4): S152–S155.
    1. Rangachari D., Yamaguchi N., VanderLaan P., Folch E., Mahadevan A., Floyd S., et al. (2015) Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88: 108–111.
    1. Reckamp K., Giaccone G., Camidge D., Gadgeel S., Khuri F., Engelman J., et al. (2014) A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 120: 1145–1154.
    1. Regales L., Gong Y., Shen R., de Stanchina E., Vivanco I., Goel A., et al. (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119: 3000–3010.
    1. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239–246.
    1. Schouten L., Rutten J., Huveneers H., Twijnstra A. (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94: 2698–2705.
    1. Sequist L., Besse B., Lynch T., Miller V., Wong K., Gitlitz B., et al. (2010) Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 3076–3083.
    1. Sequist L., Goldman J., Wakelee H., Camidge D., Yu H., Varga A., et al. (2015a) Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 33(Suppl.); abstract 8001.
    1. Sequist L., Soria J., Camidge D. (2016) Update to rociletinib data with the RECIST confirmed response rate. N Engl J Med 374:2296–2297.
    1. Sequist L., Soria J., Goldman J., Wakelee H., Gadgeel S., Varga A., et al. (2015b) Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 372: 1700–1709.
    1. Sequist L., Waltman B, Dias-Santagata D., Digumarthy S., Turke A., Fidias P., et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26.
    1. Seto T., Kato T., Nishio M., Goto K., Atagi S., Hosomi Y., et al. (2014) Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15: 1236–1244.
    1. Song H., Jung K., Yoo K., Cho J., Lee J., Lim S., et al. (2016) Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer. J Thorac Oncol 11: e45–e47.
    1. Stahel R., Dafni U., Gautschi O., Felip E., Curioni-Fontecedro A., Peters S., et al. (2015) A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF Trial. Eur J Cancer 51(Suppl. 3): S711.
    1. Stewart E., Tan S., Liu G., Tsao M. (2015) Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res 4: 67–81.
    1. Su K., Chen H., Li K., Kuo M., Yang J., Chan W., et al. (2012) Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30: 433–440.
    1. Tan D., Yang J., Leighl N., Riely G., Sequist L., Felip E., et al. (2016) Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. J Clin Oncol 34(Suppl.); abstract 9044
    1. Thress K., Paweletz C., Felip E., Cho B., Stetson D., Dougherty B., et al. (2015) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21: 560–562.
    1. Thress K., Yang J., Ahn M., Kim D., Kim S., Ohe Y., Planchard D. (2014) Levels of EGFR T790M in plasma DNA as a predictive biomarker for response to AZD9291, a mutant-selective EGFR kinase inhibitor. Ann Oncol 25(Suppl. 4): iv426–iv470.
    1. Tricker E., Xu C., Uddin S., Capelletti M., Ercan D., Ogino A., et al. (2015) Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov 5: 960–971.
    1. Vishwanathan K., Dickinson P., Bui K., Weilert D., So K., Thomas K., et al. (2015) Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291. AACR; Mol Cancer Ther 14(12 Suppl. 2); abstract B153.
    1. Wakelee H., Gadgeel S., Goldman J., Reckamp K., Karlovich C., Melnikova V., et al. (2016) Epidermal Growth Factor Receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. J Clin Oncol 34(Suppl.); abstract 9001.
    1. Yang J., Kim D., Kim S., Byoung C., Lee J. (2016a) Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol 34(Suppl.); abstract 9002.
    1. Yang J., Ramalingam H., Jänne P., Ahn M., Bazhenova L., Blackhall F., et al. (2016b) Osimertinib (AZD9291) in pre-treated patients with T790M-positive advanced NSCLC: updated phase I and pooled phase II results. J Thorac Oncol 11(Suppl. 4): S152–S155.
    1. Yang J., Wu Y., Schuler M., Sebastian M., Popat S., Yamamoto N., et al. (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16: 141–151.
    1. Yu H., Arcila M., Rekhtman N., Sima C., Zakowski M., Pao W., et al. (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19: 2240–2247.
    1. Yu H., Tian S., Drilon A., Borsu L., Riely G., Arcila M., Ladanyi M. (2015) Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncol 1: 982–984.
    1. Yu H., Spira A., Horn L., Weiss J., West H., Giaccone G., et al. (2016) Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study. J Clin Oncol 34(Suppl.); abstract 9050.
    1. Yun C., Mengwasser K., Toms A., Woo M., Greulich H., Wong K., et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070–2075.
    1. Zeng Q., Wang J., Cheng Z., Chen K., Johnström P., Varnäs K., et al. (2015) Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J Med Chem 58: 8200–8215.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅